Skip to main content

The People Nitazenes Are Killing Already Found Treatment Once. CDC Data Says the System Let Them Go.

A new CDC-led study counts 1,443 overdose deaths involving nitazenes, opioids even stronger than fentanyl, and finds the victims were more likely to have been in treatment and survived an overdose before.

ByThe Rize NewsroomNovember 22, 20262 min readNovel & Emerging Psychoactives

The people dying from nitazenes aren’t strangers to the treatment system. That’s the finding buried in a study published Friday by researchers from the CDC and two forensic labs. Counting deaths from 2019 through 2024, they found nitazenes, a family of lab-made opioids that can be far stronger than fentanyl, in 1,443 overdose deaths across 47 jurisdictions. Compared with people who died from other opioids, the people killed by nitazenes were more likely to have injected, more likely to have survived an overdose before, and more likely to have been in addiction treatment before. Somebody had them once. Then they were gone.

A prior overdose and a prior stint in treatment are the two clearest warning signs we have, and right now the system treats both as a closed file instead of an open emergency.

In plain terms, here’s what the study did. The CDC runs a national system that pulls together death records, toxicology reports and the circumstances of each overdose death, called SUDORS. The researchers paired it with data from two private forensic labs that test for new drugs. The labs usually spotted each new nitazene before the national system did, sometimes by months. Most deaths also involved fentanyl, stimulants or street benzodiazepines, so these are mixed-supply deaths, not people seeking out nitazenes. The authors say the 1,443 figure is a floor, because most medical examiners don’t routinely test for these drugs. The true count is higher, and nobody knows by how much.

The treatment finding is the one that should keep providers up at night. It doesn’t mean treatment caused these deaths. It means people who’ve been through treatment, and especially people who’ve left it, carry the highest risk of all. Tolerance drops fast after you stop using, and a supply laced with something stronger than fentanyl punishes that drop hardest. We’ve seen nitazenes turn up in vapes sold as cannabis, too.

If you’ve overdosed before, or you’ve been in treatment and you’re using again, you are exactly who this study is about, and you’re worth protecting. Naloxone still works on nitazenes, though it can take more than one dose, and it’s sold over the counter. Don’t use alone. Keep a second dose nearby.

For providers, one change this week: treat discharge and dropout as a risk event. Every person who leaves your program early, or survives an overdose, should go home with two naloxone doses and a scheduled callback within 72 hours. These people were in our programs once. The study says we didn’t keep them close enough. More data lives in The Crisis, By the Numbers and our novel and emerging substances hub.

Filed Under

sciencetreatmentNitazenesSynthetic Opioid AnalogsOverdoseGovernment DataPeer-Reviewed ResearchNaloxone

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section